The EBiSC team is working hard to implement improvements in how EBiSC operates. Due to some short-term disruption, please get in touch via Contact@EBiSC.org if the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe.

BIONi010-C-10

HNF1AP291fsinsC +/- 54-5

Gene-edited iPSC line

Stock not immediately available - enquire for details
We are currently making some changes to how EBiSC operates and because of this there is a short period of time where orders cannot be placed.

If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name BIONi010-C-10
Alternative name(s)
HNF1AP291fsinsC +/- 54-5
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
Notes No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23

Provider

Depositor Bioneer (BION)
Owner Bioneer (BION)
Distributors
EBiSC
Derivation country Denmark

External Databases

hPSCreg BIONi010-C-10
BioSamples SAMEA104619380
Cellosaurus CVCL_RM84
Wikidata Q54796752

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

hIPSC Derivation#

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
No

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Method documentation
HNF1A 54-5 flow.tif
Flow cytometry of undifferentiated cells

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: P11
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
Synonyms
  • Maturity-onset diabetes of the young
Genetic modifications
HNF1A (target)
Isogenic modification
12q24.31
NM_000545.6:c.(c.872dup)
NP_000536.5:p.(P291fsinsC)
Heterozygous
An additional cytocine has been introduced by CRISPR-Cas9 into a poly-C tract in Exon 4 of HNF1A resulting in a out of frame mutation. It is likely that the other allele has also been targeted, since western blotting did not show any HNF1A protein in Pancreatic progenitor cells compared to the control line BIONi010-C.
Mutated
HNF1A 54-5 BIONi010-C.tif
Sequencing of HNF1A 54-5 and BIONi010-C showing a heterozygous mutation in one of the alleles of HNF1A